FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3093399096> ?p ?o ?g. }

• W3093399096 endingPage "e2020425" @default.
• W3093399096 startingPage "e2020425" @default.
• W3093399096 abstract "<h3>Importance</h3> In the pivotal Multicenter Study of Oxaliplatin/5FU-LV in the Adjuvant Treatment of Colon Cancer (MOSAIC) trial, patients with high-risk stage II colon cancer (CC) had 5-year and 10-year overall survival (OS) rates of 88% and 75%, respectively, with adjuvant fluorouracil and oxaliplatin–based chemotherapy; the Bevacizumab-Avastin Adjuvant (AVANT) trial did not demonstrate a disease-free survival (DFS) benefit of adding bevacizumab to oxaliplatin-based chemotherapy in stage III CC and suggested a detrimental effect on OS. The Long-term Survival AVANT (S-AVANT) study was designed to collect extended follow-up for patients in the AVANT trial. <h3>Objective</h3> To explore the efficacy of adjuvant bevacizumab combined with oxaliplatin-based chemotherapy in patients with high-risk, stage II CC. <h3>Design, Setting, and Participants</h3> This prespecified secondary end point analysis of the AVANT and S-AVANT studies included 573 patients with curatively resected high-risk stage II CC and at least 1 of the following criteria: stage T4, bowel obstruction or perforation, blood and/or lymphatic vascular invasion and/or perineural invasion, age younger than 50 years, or fewer than 12 nodes analyzed. The AVANT study was a multicenter randomized stage 3 clinical trial. Data were collected from December 2004 to February 2019, and data for this study were analyzed from March to September 2019. <h3>Intervention</h3> Patients were randomly assigned to receive 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX4), FOLFOX4 with bevacizumab, or capecitabine and oxaliplatin (XELOX) with bevacizumab. <h3>Main Outcomes and Measures</h3> The primary end points of this secondary analysis were DFS and OS in patients with high-risk stage II CC. <h3>Results</h3> The AVANT study included 3451 patients, of whom 573 (16.6%) had high-risk stage II CC (192 [33.5%] randomized to FOLFOX4 group; 194 [33.9%] randomized to FOLFOX4 with bevacizumab group; 187 [32.6%] randomized to XELOX with bevacizumab group). With a median (interquartile range) age of 57.0 (47.2-65.7) years, the study population comprised 325 men (56.7%) and 248 women (43.3%). After a median (interquartile range) follow-up of 6.9 (6.1-11.3) years, the 3-year DFS and 5-year OS rates were 88.2% (95% CI, 83.7%-93.0%) and 89.7% (95% CI, 85.4%-94.2%) in the FOLFOX4 group, 86.6% (95% CI, 81.8%-91.6%) and 89.7% (95% CI, 85.4%-94.2%) in the FOLFOX4 with bevacizumab group, and 86.7% (95% CI, 81.8%-91.8%) and 93.2% (95% CI, 89.6%-97.0%) in the XELOX with bevacizumab group, respectively. The DFS hazard ratio was 0.94 (95% CI, 0.59-1.48;<i>P</i> = .78) for FOLFOX4 with bevacizumab vs FOLFOX4 and 1.07 (95% CI, 0.69-1.67;<i>P</i> = .76) for XELOX with bevacizumab vs FOLFOX4. The OS hazard ratio was 0.92 (95% CI, 0.55-1.55;<i>P</i> = .76) for FOLFOX4 with bevacizumab vs FOLFOX4 and 0.85 (95% CI, 0.50-1.44;<i>P</i> = .55) for XELOX with bevacizumab vs FOLFOX4. <h3>Conclusions and Relevance</h3> In this secondary analysis of data from the AVANT trial, adding bevacizumab to oxaliplatin-based chemotherapy was not associated with longer DFS or OS in patients with high-risk stage II CC. The findings suggest that the definition of high-risk stage II CC needs to be revisited. <h3>Trial Registration</h3> ClinicalTrial.gov Identifiers: AVANT (NCT00112918); S-AVANT (NCT02228668)" @default.
• W3093399096 created "2020-10-22" @default.
• W3093399096 creator A5004165781 @default.
• W3093399096 creator A5006121686 @default.
• W3093399096 creator A5012453950 @default.
• W3093399096 creator A5013525685 @default.
• W3093399096 creator A5015509025 @default.
• W3093399096 creator A5022007986 @default.
• W3093399096 creator A5029465085 @default.
• W3093399096 creator A5030933228 @default.
• W3093399096 creator A5035568045 @default.
• W3093399096 creator A5038131926 @default.
• W3093399096 creator A5047738337 @default.
• W3093399096 creator A5050929435 @default.
• W3093399096 creator A5053639618 @default.
• W3093399096 creator A5054670872 @default.
• W3093399096 creator A5058463503 @default.
• W3093399096 creator A5059501670 @default.
• W3093399096 creator A5061007808 @default.
• W3093399096 creator A5063860482 @default.
• W3093399096 creator A5069539916 @default.
• W3093399096 creator A5072207853 @default.
• W3093399096 creator A5074210261 @default.
• W3093399096 creator A5075053811 @default.
• W3093399096 creator A5079480540 @default.
• W3093399096 creator A5090645179 @default.
• W3093399096 creator A5091727687 @default.
• W3093399096 date "2020-10-19" @default.
• W3093399096 modified "2023-10-13" @default.
• W3093399096 title "Association of Bevacizumab Plus Oxaliplatin-Based Chemotherapy With Disease-Free Survival and Overall Survival in Patients With Stage II Colon Cancer" @default.
• W3093399096 cites W1561803312 @default.
• W3093399096 cites W1845706120 @default.
• W3093399096 cites W1960485012 @default.
• W3093399096 cites W1985712533 @default.
• W3093399096 cites W2020426410 @default.
• W3093399096 cites W2029938510 @default.
• W3093399096 cites W2098499757 @default.
• W3093399096 cites W2098916599 @default.
• W3093399096 cites W2109740395 @default.
• W3093399096 cites W2111413787 @default.
• W3093399096 cites W2118950501 @default.
• W3093399096 cites W2125857654 @default.
• W3093399096 cites W2126588279 @default.
• W3093399096 cites W2137408681 @default.
• W3093399096 cites W2138985803 @default.
• W3093399096 cites W2157769714 @default.
• W3093399096 cites W2171232394 @default.
• W3093399096 cites W2313857605 @default.
• W3093399096 cites W2314635417 @default.
• W3093399096 cites W2410989399 @default.
• W3093399096 cites W2460179076 @default.
• W3093399096 cites W2469345929 @default.
• W3093399096 cites W2795004907 @default.
• W3093399096 cites W2977571468 @default.
• W3093399096 cites W4243550142 @default.
• W3093399096 cites W4292528167 @default.
• W3093399096 doi "https://doi.org/10.1001/jamanetworkopen.2020.20425" @default.
• W3093399096 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7573695" @default.
• W3093399096 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33074326" @default.
• W3093399096 hasPublicationYear "2020" @default.
• W3093399096 type Work @default.
• W3093399096 sameAs 3093399096 @default.
• W3093399096 citedByCount "9" @default.
• W3093399096 countsByYear W30933990962020 @default.
• W3093399096 countsByYear W30933990962021 @default.
• W3093399096 countsByYear W30933990962022 @default.
• W3093399096 countsByYear W30933990962023 @default.
• W3093399096 crossrefType "journal-article" @default.
• W3093399096 hasAuthorship W3093399096A5004165781 @default.
• W3093399096 hasAuthorship W3093399096A5006121686 @default.
• W3093399096 hasAuthorship W3093399096A5012453950 @default.
• W3093399096 hasAuthorship W3093399096A5013525685 @default.
• W3093399096 hasAuthorship W3093399096A5015509025 @default.
• W3093399096 hasAuthorship W3093399096A5022007986 @default.
• W3093399096 hasAuthorship W3093399096A5029465085 @default.
• W3093399096 hasAuthorship W3093399096A5030933228 @default.
• W3093399096 hasAuthorship W3093399096A5035568045 @default.
• W3093399096 hasAuthorship W3093399096A5038131926 @default.
• W3093399096 hasAuthorship W3093399096A5047738337 @default.
• W3093399096 hasAuthorship W3093399096A5050929435 @default.
• W3093399096 hasAuthorship W3093399096A5053639618 @default.
• W3093399096 hasAuthorship W3093399096A5054670872 @default.
• W3093399096 hasAuthorship W3093399096A5058463503 @default.
• W3093399096 hasAuthorship W3093399096A5059501670 @default.
• W3093399096 hasAuthorship W3093399096A5061007808 @default.
• W3093399096 hasAuthorship W3093399096A5063860482 @default.
• W3093399096 hasAuthorship W3093399096A5069539916 @default.
• W3093399096 hasAuthorship W3093399096A5072207853 @default.
• W3093399096 hasAuthorship W3093399096A5074210261 @default.
• W3093399096 hasAuthorship W3093399096A5075053811 @default.
• W3093399096 hasAuthorship W3093399096A5079480540 @default.
• W3093399096 hasAuthorship W3093399096A5090645179 @default.
• W3093399096 hasAuthorship W3093399096A5091727687 @default.
• W3093399096 hasBestOaLocation W30933990961 @default.
• W3093399096 hasConcept C121608353 @default.
• W3093399096 hasConcept C126322002 @default.
• W3093399096 hasConcept C141071460 @default.
• W3093399096 hasConcept C143998085 @default.

• next